Concepedia

Kumar Budur

KB

3

Publications

382

Citations

3

H-Index

2022

Active since

Affiliations

AbbVie (United States)(Current)

The University of Adelaide

Westmead Hospital

University of Alabama at Birmingham

The University of Sydney

Kumar Budur is an author at AbbVie (United States) specializing in neurology, parkinson disease, and movement disorders.

Top concepts

Publications per year

2022–2023

3

Publications

3

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Michael J. Soileau, Jason Aldred, Kumar Budur et al. · The Lancet Neurology · 2022 · 172 citations

, , +3

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Hana Florian, Deli Wang, Steven E. Arnold et al. · Brain · 2023 · 119 citations · Full text

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred, Eric Freire-Álvarez, Angelo Antonini et al. · Neurology and Therapy · 2023 · 91 citations · Full text

Rows per page

1–3 of 3